This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Biogen, Inc.

Drug Names(s): LTBR-Fc, BG9924, Lymphotoxin Beta Soluble Receptor

Description: Biogen scientists were involved in the discovery of lymphotoxin a and b, members of the tumor necrosis factor (TNF) family of proteins. Lymphotoxin binds to both the TNF receptor and to the lymphotoxin b receptor. Preclinical data suggest that lymphotoxin inhibitors will act in a manner similar to TNFa inhibitors such as Enbrel and Remicade, perhaps complementing their activity.

Baminercept News

Pink Sheet R&D In Brief

Pink Sheet R&D In Brief

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug